MicroRNA-425-5p Is Involved in the Development of Diabetic Retinopathy and Regulates the Proliferation and Migration of Retinal Microvascular Endothelial Cells

Abstract

<b><i>Introduction:</i></b> The objective of this article was to detect the expression pattern and clinical value of miR-425-5p in diabetic retinopathy (DR) patients and investigate its effect on the proliferation and migration of human retinal microvascular endothelial cells (HRMECs) in a high glucose (HG) state. <b><i>Methods:</i></b> The serum miR-425-5p level of the subjects was determined using quantitative real-time PCR. The diagnostic value of serum miR-425-5p was validated using the receiver operating characteristic curve. Pearson analysis detected the correlation between clinical indicators and microRNA. The influence of miR-425-5p on cell proliferation and migration under HG conditions was calculated by using Cell Counting Kit-8 and Transwell assay. <b><i>Results:</i></b> Serum miR-425-5p levels showed a gradual increasing trend in the healthy control group, the diabetic mellitus patients without DR, and DR patients. Moreover, the levels of miR-425-5p in proliferative DR (PDR) patients were elevated than that of non-PDR (NPDR) patients. Furthermore, upregulated miR-425-5p had a high diagnostic value for DR patients and can distinguish PDR patients from NPDR patients. The expression of miR-425-5p was significantly positively correlated with the fasting plasma glucose, glycosylated hemoglobin (HbA1C), homeostasis model assessment of insulin resistance, and disease course of the patients. Under HG conditions, overexpression of miR-425-5p promoted HRMEC proliferation and migration, while inhibition of miR-425-5p led to opposite results. <b><i>Conclusion:</i></b> Present research confirmed that serum miR-425-5p levels in DR are marked by elevation. High expression of miR-425-5p can be used as a feasible diagnostic biomarker for DR patients and can predict the development and severity of DR. Moreover, inhibiting the expression of miR-425-5p levels under the condition of hyperglycemia may be used as a valuable therapeutic strategy for preventing the pathogenesis of DR.

Circulating MicroRNAs as Potential Diagnostic Biomarkers for Diabetic Retinopathy: A Meta-Analysis

“…In total, 25 documents (spanning years 2014 to 2022) included in this meta-analysis involved 52 studies ( 11 , 18 , 20 , 25 – 46 ) ( Table 1 ), all of which were case-control studies that included a total of 1987 patients with DR and 1771 non-DR controls, with the source of controls being diabetic patients not diagnosed with DR, healthy population, and patients with cataract. Among these 52 studies, 41 studies reported a single miRNA, and 11 studies discussed a panel of miRNAs.…”

Sestrin2 ameliorates diabetic retinopathy by regulating autophagy and ferroptosis

“…The blood glucose level of the mice was detected, and compared with the NC group, the blood glucose of DM mice increased significantly and was greater than 16.7 mmol/L. Glycated hemoglobin is an important standard for diabetes diagnosis and treatment monitoring, and the increase of glycated hemoglobin can promote the frequency of DR lesions (Liu et al 2022c ). And the glycated hemoglobin level was also significantly increased in the DM group.…”

“…DR is characterized by hyperglycemia, which causes changes in retinal microvascular function and integrity, leading to progressive retinal ischemia and angiogenesis (Deng et al 2022 ). In the treatment of DR, the first is to control blood sugar or to delay the occurrence of DR by changing lifestyle, improving insulin resistance and repairing damaged islet cell function, or to treat DR by laser surgery, vitrectomy and other treatments (Deng et al 2022 ; Liu et al 2022a , b , c ). However, the current treatment results of DR are often unsatisfactory, so it is necessary to explore more specific and precise molecular mechanisms to determine more effective prevention and treatment of DR.…”

Role of MicroRNA in linking diabetic retinal neurodegeneration and vascular degeneration

“…After 3 months of treatment with empagliflozin, miR-21 and miR-92 were significantly reduced and endothelial dysfunction was alleviated in patients with heart failure with preserved ejection fraction ( 90 ). MiR-18b ( 79 ), miR-20b-5p ( 80 ), and miR-425-5p ( 91 ) promoted HRMEC proliferation and migration. Down-regulated MiR-126-3p in diabetic rat retina attenuates experimental diabetic retinopathy by targeting PLK4 to inhibit endothelial cell proliferation and migration ( 81 ).…”